Extracorporeal Membrane Oxygenation in Refractory Cardiogenic Shock
DOI:
https://doi.org/10.1532/hsf.3263Keywords:
extracorporeal membrane oxygenation(ECMO), refractory, cardiogenic, shockAbstract
Background: Many clinicians do not know under what exact conditions extracorporeal membrane oxygenation (ECMO) can get the best results. In this study, we explored the optimal indications for ECMO in patients with refractory cardiogenic shock.
Methods: From October 2014 to November 2019, 23 patients with refractory cardiogenic shock were treated with ECMO in our hospital, including 11 cases with acute left anterior myocardial infarction, 3 with acute left inferior and right ventricular myocardial infarction, and 9 with fulminant myocarditis. These cases were divided into survivors (n = 10) and nonsurvivors (n = 13), and the clinical data of the 2 groups were compared.
Results: The weaning rate of ECMO was 60.9%. The discharge survival rate was 43.5%. There were significant differences in age, sequential organ failure assessment (SOFA) score, vasoactive-inotropic (VIS) score, lactic acid concentrations, primary disease, and smoking history between survivors and nonsurvivors before ECMO (P < .05). There were significant differences in blood pressure (systolic and diastolic), oxygen partial pressure, and left ventricular ejection fraction between survivors and nonsurvivors 1 day before the removal of ECMO (P < .05).
Conclusions: The reversibility of the primary disease causing refractory cardiogenic shock is critical to the survival rate of ECMO. Etiological treatment is essential, and extra attention should be paid to the use of ECMO in patients with irreversible primary disease. ECMO should be regarded as a first aid device and is not suitable for long-term cardiac assistance; left ventricular assist or heart transplantation is a better option.
References
Chen ZW, Yu ZQ, Yang HB, et al. Rapid predictors for the occurrence of reduced left ventricular ejection fraction between LAD and non-LAD related ST-elevation myocardial infarction. BMC Cardiovasc Disord 2016;16:3.
Chong SZ, Fang CY, Fang HY, et al. Associations with the in-hospital survival following extracorporeal membrane oxygenation in adult acute fulminant myocarditis. J Clin Med 2018;7:E452.
Goldberg RJ, Makam RC, Yarzebski J, McManus DD, Lessard D, Gore JM. Decade-long trends (2001-2011) in the incidence and hospital death rates associated with the in-hospital development of cardiogenic shock after acute myocardial infarction. Circ Cardiovasc Qual Outcomes 2016;9:117-125.
Kolte D, Khera S, Aronow WS, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST elevation myocardial infarction in the United States. J Am Heart Assoc 2014;3:e000590.
Lee SN, Hwang YM, Kim GH, et al. Primary percutaneous coronary intervention ameliorates complete atrioventricular block complicating acute inferior myocardial infarction. Clin Interv Aging 2014;9:2027-2031.
Liao X, Li B, Cheng Z. Extracorporeal membrane oxygenation in adult patients with acute fulminant myocarditis: Clinical outcomes and risk factor analysis. Herz 2018;43:728-732.
Lin KM, Li MH, Hsieh KS, et al. Impact of extracorporeal membrane oxygenation on acute fulminant myocarditis-related hemodynamic compromise arrhythmiain children. Pediatr Neonatol 2016;57:480-487.
Matsumoto M, Asaumi Y, Nakamura Y, et al. Clinical determinants of successful weaning from extracorporeal membrane oxygenation in patients with fulminant myocarditis. ESC Heart Fail 2018;5:675-684.
Montero S, Aissaoui N, Tadié JM, et al. Fulminant giant-cell myocarditis on mechanical circulatory support: Management and outcomes of a French multicentre cohort. Int J Cardiol 2018;253:105-112.
Nasr VG, Raman L, Barbaro RP, et al. Highlights from the Extracorporeal Life Support Organization Registry: 2006-2017. ASAIO J 2019;65:537-544.
Rejmstad P, Johansson JD, Haj-Hosseini N, Wardell K. A method for monitoring of oxygen saturation changes in brain tissue using diffuse reflectance spectroscopy. J Biophotonics 2017;10:446-455.
Reynolds HR, Hochman JS. Cardiogenic shock: Current concepts and improving outcomes. Circulation 2008;117:686-697.
Sandhu A, McCoy LA, Negi SI, et al. Use of mechanical circulatory support in patients undergoing percutaneous coronary intervention: Insights from the National Cardiovascular Data Registry. Circulation 2015;132:1243-1251.
Smarz K, Zaborska B, Jaxa-Chamiec T, Tysarowski M, Budaj A. Right ventricular systolic function as a marker of prognosis after ST-elevation inferior myocardial infarction 5-year follow-up. Int J Cardiol 2016;221:549-553.
Thiele H, Ohman EM, Desch S, Eitel I, de Waha S. Management of cardiogenic shock. Eur Heart J 2015;36:1223-1230.
Thiele H, Zeymer U, Neumann FJ, et al. IABP SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012;367:1287-1296.
